When the $10K brand name drug is more affordable than its $450 generic: How PBMs control the system

Pharmacy benefit managers — the much-maligned middlemen between drug manufacturers and health insurers — often tilt the market, 80% of which is controlled by 3 of the largest PBMs, in their own and unusual ways.